Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Travere Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TVTX
Nasdaq
2834
www.travere.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Travere Therapeutics, Inc.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov 12th, 2026 3:00 pm
Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why
- Nov 3rd, 2026 2:36 pm
Travere Therapeutics to Participate at Upcoming Investor Conferences
- Nov 3rd, 2026 2:30 pm
Travere Therapeutics, Inc. Q3 2026 Earnings Call Summary
- Nov 3rd, 2026 6:30 am
Why Travere Therapeutics (TVTX) Could Be 34% Undervalued On Its Q3 Loss
- Nov 3rd, 2026 1:10 am
Travere Therapeutics (TVTX) Stock Looks Fully Priced After Its 7x Run
- Nov 3rd, 2026 12:06 am
What Could Travere Therapeutics (TVTX) New Biomarker Data Mean For IgA Nephropathy?
- Nov 2nd, 2026 11:14 pm
Travere (TVTX) Q3 2026 Earnings Call Transcript
- Nov 2nd, 2026 9:59 pm
Travere: Q3 Earnings Snapshot
- Nov 2nd, 2026 9:37 pm
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
- Nov 2nd, 2026 5:14 pm
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
- Nov 2nd, 2026 3:30 pm
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
- Nov 2nd, 2026 2:55 pm
Travere Therapeutics Reports Third Quarter 2026 Financial Results
- Nov 2nd, 2026 2:01 pm
A $2 Billion Fund Bought These 3 Stocks Last Quarter
- Nov 2nd, 2026 3:40 am
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
- Oct 28th, 2026 2:20 pm
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
- Oct 28th, 2026 7:00 am
Travere Therapeutics to Report Third Quarter 2026 Financial Results
- Oct 26th, 2026 2:30 pm
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
- Oct 23rd, 2026 5:20 pm
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
- Oct 22nd, 2026 8:27 am
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
- Oct 22nd, 2026 7:00 am
Scroll